# Semaglutide 2 mg vs 1 mg: SUSTAIN FORTE | GLP1Nerds Canonical: https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/ Published: 2026-10-25 Updated: 2026-10-25 SUSTAIN FORTE supports additional glucose lowering with 2 mg semaglutide in diabetes. The weight comparison changes with the analysis used. [Research](https://glp1nerds.com/research/)/Medications Medications # Semaglutide 2 mg vs 1 mg: reading SUSTAIN FORTE SUSTAIN FORTE supports additional glucose lowering with 2 mg semaglutide in diabetes. The weight comparison changes with the analysis used. OC[Owen Calder](https://glp1nerds.com/authors/owen-calder/)Founding Editor · Updated October 2026 Editorial analysis · Not a clinical consultation ![Two equal-width bands identify the semaglutide doses compared in SUSTAIN FORTE.](https://glp1nerds.com/assets/editorial/semaglutide-higher-dose-sustain-forte.svg) Conceptual trial-dose diagram, not a dosing recommendation or a graph of comparative benefit. The article distinguishes HbA1c and body-weight outcomes and their estimands. ## What to know - SUSTAIN FORTE supports additional glucose lowering with 2 mg semaglutide in diabetes. The weight comparison changes with the analysis used. - Population, comparison and follow-up determine what the finding can establish. - A study average is not an individualized outcome prediction. ## The question was treatment intensification in diabetes SUSTAIN FORTE tested whether a higher weekly semaglutide dose could provide additional glucose lowering for adults whose type 2 diabetes remained inadequately controlled. It was not a trial of choosing an obesity program or comparing semaglutide with another ingredient. Its glucose finding favored 2 mg over 1 mg. The weight result requires a more careful description because the two prespecified analyses did not give the same statistical conclusion. That distinction makes this study useful for reading treatment claims: a higher dose can improve a particular average outcome without proving that every additional endpoint improves clearly or that everyone should receive it.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) For the related decision, read [the connected evidence](https://glp1nerds.com/research/semaglutide-dulaglutide-sustain7/). ## Who entered the trial The double-blind study randomized 961 adults receiving metformin, with or without a sulfonylurea, to weekly semaglutide 2 mg or 1 mg for 40 weeks. Entry required HbA1c between 8.0% and 10.0%. The active comparator is important: investigators were measuring an incremental effect beyond an already effective semaglutide dose, not the full effect of starting semaglutide compared with no medicine. A small between-group difference can coexist with substantial changes within both groups. The randomized design also prevents the common problem of comparing higher-dose patients in one setting with lower-dose patients who had different starting characteristics elsewhere.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) ## Keep the glucose units explicit The primary outcome was change in HbA1c, a measure of longer-term glucose exposure. In the treatment-policy analysis, the estimated difference was 0.18 percentage points in favor of 2 mg, with a 95% confidence interval from 0.04 to 0.31 points in that direction. The trial-product analysis also favored the higher dose. These are percentage-point differences in HbA1c. They are not the same as a percentage reduction in heart attacks, kidney disease or mortality. When judging a headline, ask whether the number describes the laboratory measure, a clinical event, a relative change or an absolute difference. Those quantities answer different questions.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) [\[2\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-2) ## Why two analyses appear in the report The treatment-policy estimand addresses assignment to the strategy regardless of treatment discontinuation or rescue therapy. The trial-product estimand addresses continued study treatment without rescue under its assumptions. Neither label simply means good data versus bad data. They frame different questions about treatment and require different handling of observations after treatment changes. For someone considering a long-term medicine, both efficacy during continued use and the practical consequences of starting the strategy can matter. A responsible summary identifies which result it uses rather than selecting the most favorable analysis separately for every endpoint and presenting that collection as one unqualified answer.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) For the related decision, read [our support-model comparison](https://glp1nerds.com/compare/clinic-vs-pharmacy-access/). ## Weight is where the qualification becomes visible The trial-product analysis estimated an additional 0.93 kg of weight reduction with 2 mg, with a confidence interval excluding zero. In the treatment-policy analysis, the estimated additional reduction was 0.77 kg, but its confidence interval crossed zero and the reported P value was 0.054. That latter result did not establish statistical superiority for weight. It does not prove that the two doses have identical weight effects. It does mean that a simple claim of proven weight superiority without the analysis attached is too broad. The current Ozempic prescribing information explicitly describes the weight difference in its analysis as not statistically significant.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) [\[2\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-2) ## An increment is different from the total response A reader can easily confuse a within-group reduction with the added benefit of the higher dose. The useful comparison for this trial is the difference between randomized groups. Someone already doing well on a lower dose should not read the entire higher-dose group change as the extra result available from escalation. Starting glucose, other medicines, tolerability and treatment goals all influence how a clinician interprets an incremental effect. Nor does the trial specify an individual's future response. Its averages describe groups followed under a protocol, and the uncertainty around a group contrast cannot be converted into a promised amount of personal weight loss. ## Safety belongs beside the benefit Gastrointestinal disorders were the most frequently reported adverse events in the trial. The higher-dose result should therefore be read alongside tolerability and continuation, rather than as a pure arithmetic exercise. Current labeling contains a boxed thyroid C-cell tumor warning and contraindications, as well as warnings concerning pancreatitis, dehydration-related kidney injury and other clinical issues. Concomitant insulin or insulin secretagogues also require attention to hypoglycemia risk. This article is not an escalation schedule or a complete safety checklist. A clinician needs the actual medication list, symptoms and medical history before deciding whether an additional glycemic effect justifies a particular treatment change.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) [\[2\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-2) For the related decision, read [our Form Health review](https://glp1nerds.com/reviews/form-health/). ## The formulation and indication remain specific SUSTAIN FORTE studied injected semaglutide in a diabetes treatment setting. Oral semaglutide and compounded preparations are different formulations, and obesity-dose evidence belongs to its own trial program. The presence of the ingredient name is insufficient to treat those products as interchangeable. The prescribing information identifies the approved presentation, indications and administration requirements. If a program cites this trial while offering a different preparation, ask which evidence supports the exact product being dispensed. The study can inform a conversation about the studied injection; it cannot establish equivalent absorption, quality or outcomes for a preparation that was never tested in this protocol.[\[2\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-2) ## Other comparisons cannot be stitched into a new trial SUSTAIN 7 compared semaglutide with dulaglutide at the doses and conditions in that earlier diabetes trial. It provides useful context for why active comparators and dose selection matter, but it did not test the SUSTAIN FORTE 2 mg comparison. Combining the most favorable semaglutide result from one paper with a comparator result from another would lose randomization across those groups. Differences in entry criteria, background treatment and follow-up could explain part of an apparent ranking. Read the connected evidence as a set of distinct questions rather than a league table in which every dose and medicine has faced every other option.[\[3\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-3) ## A focused appointment question is more useful than a dose ranking The practical question is whether additional glucose lowering is needed and which available approach fits the patient's broader care. Ask how the prescriber weighs the incremental HbA1c effect, the qualified weight result, adverse effects and access. Also ask how response and tolerability will be reviewed, and who coordinates other diabetes medicines if the regimen changes. Novo Nordisk funded SUSTAIN FORTE; recognizing the sponsor belongs with evaluating the randomized design and reported analyses. The defensible conclusion is specific: the higher studied dose improved average glycemic control in this population, while the weight-superiority claim depends on the estimand. That is useful evidence without turning it into a universal escalation recommendation.[\[1\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-1) [\[2\]](https://glp1nerds.com/research/semaglutide-higher-dose-sustain-forte/#reference-2) ## Read the evidence alongside the practical choice [the connected evidence](https://glp1nerds.com/research/semaglutide-dulaglutide-sustain7/) [our support-model comparison](https://glp1nerds.com/compare/clinic-vs-pharmacy-access/) [our Form Health review](https://glp1nerds.com/reviews/form-health/) ## Sources - [Frias et al. SUSTAIN FORTE randomized trial (2021) (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/34293304/) - [Ozempic current prescribing information, section 14 and safety information (opens in a new tab)](https://www.novo-pi.com/ozempic.pdf) - [Pratley et al. SUSTAIN 7 randomized trial (2018) (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/29397376/) Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician. ## Keep exploring. [Research library](https://glp1nerds.com/research/) Medications ### [Semaglutide vs dulaglutide: reading SUSTAIN 7](https://glp1nerds.com/research/semaglutide-dulaglutide-sustain7/) SUSTAIN 7 compared specific weekly doses in type 2 diabetes. Its glucose and weight results do not settle every current prescribing choice. Owen Calder Medications ### [Oral semaglutide vs liraglutide: PIONEER 4](https://glp1nerds.com/research/oral-semaglutide-liraglutide-pioneer4/) PIONEER 4 compared an oral semaglutide formulation with injected liraglutide in diabetes. Noninferiority, dose and analysis define its meaning. Owen Calder Medications ### [Semaglutide vs tirzepatide: what the direct trial answers](https://glp1nerds.com/research/semaglutide-vs-tirzepatide/) The strongest comparison concerns specific injectable doses, a defined population and 72 weeks of follow-up. Owen Calder